Africa's HPV vaccine scale-up

Overview

Updated May 31

Cervical cancer kills roughly one African woman every seven minutes. On April 29, 2026, Burundi became the latest country to give its girls a shot at avoiding that fate, launching a national human papillomavirus (HPV) vaccination program with backing from Gavi, UNICEF, and the World Health Organization (WHO).

The launch is one piece of a broader shift. Since 2019, the number of African countries running HPV vaccination programs has nearly tripled, from 11 to 31. A vaccine once associated with wealthy-country health systems is now reaching girls in some of the world's poorest places.

The expansion is part of a coordinated push to make cervical cancer the first cancer that humanity eliminates as a public health problem.

Why it matters

Nearly all cervical cancer is caused by a virus a vaccine can prevent. The women dying from it are overwhelmingly in countries that until recently had no access.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

350K

Annual cervical cancer deaths worldwide

About 94% occur in low- and middle-income countries.

African countries with HPV programs

Up from 11 in 2019; Burundi joins the list in 2026.

47%

Africa HPV coverage at end of 2024

More than double the 18% recorded in 2019.

90%

WHO target by 2030

Share of girls fully vaccinated by age 15 needed for elimination.

1.4M

Future deaths Gavi projects averted

From the 86 million girls reached through its program by end of 2025.

1,126

Burundi cervical cancer deaths, 2017-2022

From 1,581 diagnosed cases over the same period.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Fidèle Nkezabahizi

Minister of Public Health, Burundi

Leading the national HPV rollout

Marthe Sylvie Essengue Elouma

Senior Country Manager, Gavi

Coordinating Gavi support for Burundi's rollout

France Bégin

UNICEF Representative in Burundi

Supporting program implementation

Organizations Involved

Gavi, the Vaccine Alliance

International public-private partnership

Primary funder and coordinator of HPV scale-up in low-income countries

A Geneva-based alliance that pools donor money to negotiate vaccine prices and co-finance immunization programs in the world's poorest countries.

World Health Organization

United Nations agency

Sets global cervical cancer elimination targets

The UN agency responsible for global public health policy, technical guidance, and disease elimination strategy.

United Nations Children's Fund (UNICEF)

United Nations agency

Vaccine procurement and delivery partner

The UN children's agency, which procures vaccines at scale and supports country-level immunization programs.

Timeline

April 2011 April 2026

8 events Latest: April 29th, 2026 · 4 months ago

Tap a bar to jump to that date

April 2026
Burundi launches national HPV vaccination program
Latest Program Launch

Burundi adds HPV vaccine to routine immunization for girls aged 9-14, combining school-based delivery with community outreach to reach girls outside the education system.
April 29th, 2026
November 2025
Sierra Leone exceeds HPV vaccination target
Program Milestone

A government-led campaign reaches 116% of its target, vaccinating more than one million adolescent girls.
November 1st, 2025
October 2023
Nigeria launches HPV program for 7.7 million girls
Program Launch

Africa's most populous country begins HPV vaccination, dramatically expanding the regional total of girls covered.
October 24th, 2023
December 2022
Gavi approves $600M+ HPV program revitalization
Funding

Gavi's board commits over $600 million through 2025 with a new target of reaching 86 million girls and averting 1.4 million future cervical cancer deaths.
December 1st, 2022
April 2022
WHO recommends single-dose HPV schedule
Policy

After data showed one dose offers comparable protection to two or three, WHO endorses single-dose schedules, cutting program cost and logistics roughly in half.
April 11th, 2022
November 2020
WHO launches global cervical cancer elimination strategy
Policy

WHO formally adopts the 90-70-90 targets, defining what elimination means in measurable terms and giving countries a shared scoreboard.
November 17th, 2020
January 2016
Burundi begins HPV pilot in Ngozi and Rumonge
Pilot

A two-year pilot vaccinates more than 12,000 girls aged 9-13 across two health districts, achieving 85% coverage and laying the operational groundwork for a national program.
January 1st, 2016
April 2011
Rwanda becomes first African country to launch national HPV program
Program Launch

Rwanda vaccinates 93,888 sixth-grade girls in its first round, reaching 95% coverage and proving population-scale HPV vaccination is feasible in a low-income country.
April 26th, 2011

Scenarios

Africa hits 90% HPV coverage target by 2030

Unlikely

Discussed by: WHO Regional Office for Africa, Gavi, The Lancet Global Health

Continental coverage continues its current trajectory—from 18% in 2019 to 47% in 2024—and reaches 90% by 2030. This requires the remaining African countries without programs to launch quickly, current programs to scale toward universal reach, and donor funding to hold through the next Gavi replenishment cycle. A handful of countries including Rwanda, Botswana, and Sierra Leone are already at or above the threshold, providing a template.

Funding shortfalls slow rollout, leaving coverage stalled below 70%

Likely

Discussed by: Gavi, Devex, World Bank

Donor fatigue, competing health priorities, and post-pandemic budget constraints leave Gavi unable to fully fund continued scale-up. Gavi has publicly estimated that current funding gaps could result in 600,000 fewer lives saved by the end of the decade. Coverage plateaus in the 50-70% range across much of the continent—enough to prevent many deaths but not enough to drive cervical cancer toward elimination.

Single-dose schedule and self-sampling screening accelerate elimination

Possible

Discussed by: WHO, IARC, The Lancet

The 2022 single-dose recommendation roughly halves per-girl program cost, freeing resources for the screening and treatment legs of the 90-70-90 strategy. Combined with rapid scale-up of HPV self-sampling screening in adult women, the next decade sees not just rising vaccination but the first measurable decline in cervical cancer incidence in sub-Saharan Africa.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

1967-1980

WHO smallpox eradication (1980)

WHO's intensified smallpox eradication program coordinated mass vaccination across more than 50 countries, ending in the disease's certified eradication in 1980—the only human disease ever fully eliminated.

Then

Smallpox transmission ceased, ending an estimated 300 million deaths the disease had caused in the 20th century alone.

Now

The campaign established the playbook for vaccine-led disease elimination: clear targets, coordinated international financing, and country-level execution backed by global technical guidance.

Why this matters now

WHO's 90-70-90 framework borrows directly from the smallpox model. Cervical cancer cannot be eradicated like smallpox—HPV will keep circulating—but the disease it causes can be driven below epidemiological significance using the same combination of vaccination, surveillance, and global coordination.

2007-present

Australia's HPV elimination trajectory

Australia launched a national HPV program in 2007 with high coverage of both girls and, from 2013, boys. By the early 2020s, modeling showed Australia on track to become the first country to eliminate cervical cancer as a public health problem, possibly by 2035.

Then

HPV infection rates among young Australian women fell more than 90% within a decade, and rates of high-grade cervical lesions dropped sharply in vaccinated cohorts.

Now

Australia is now the canonical proof point that elimination is achievable in a real population—not just a modeling exercise—provided coverage is high and screening is integrated.

Why this matters now

Australia shows what the destination looks like when the 90-70-90 strategy works. Burundi and its peers are at the start of a path Australia walked with vastly more resources—the question is whether the single-dose schedule and Gavi's financing can let lower-income countries arrive at the same place.

April 2011

Rwanda's national HPV launch (2011)

Rwanda became the first African country—and the first low-income country anywhere—to introduce HPV vaccination at population scale, after President Paul Kagame's government negotiated direct access to Merck's Gardasil. In its first round, 93,888 sixth-grade girls received the vaccine, reaching 95% coverage.

Then

Rwanda demonstrated that high HPV coverage was achievable in a low-income setting, contradicting the assumption that the vaccine was only viable for wealthy countries.

Now

Subsequent surveillance showed HPV-16/18 infection rates in vaccinated cohorts falling sharply, providing the first hard evidence that the vaccine works at population scale in sub-Saharan Africa and giving every later rollout a working template.

Why this matters now

Burundi's launch follows the operational model Rwanda established 15 years earlier: school-based delivery anchored to a specific girls' age group, with community outreach for those outside school. Rwanda showed it could be done; Burundi is one more country choosing to do it.